TNF inhibitor

This page covers all TNF inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting TNF-α (Tumor Necrosis Factor-alpha), TNF (Tumor Necrosis Factor), TNF-α (tumor necrosis factor-alpha).

Targets

TNF-α (Tumor Necrosis Factor-alpha) · TNF (Tumor Necrosis Factor) · TNF-α (tumor necrosis factor-alpha) · TNF (tumor necrosis factor) · TNF · TNF-α · TNF-alpha

Marketed (4)

• Reduced doses of anti-TNF · Spanish Clinical Pharmacology Society · Immunology
  Reduced doses of anti-TNF agents lower the concentration of tumor necrosis factor inhibitors to minimize immunosuppression while maintaining therapeutic benefit.
• Anti-TNF Therapy · Takeda · Immunology
  Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
• Standard dose of TNFi · University Health Network, Toronto · Immunology
  TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.
• TNF blocker · Centre Hospitalier Universitaire de Saint Etienne · Immunology
  TNF blockers inhibit tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.

Phase 3 pipeline (7)

• TNFR:Fc · National Eye Institute (NEI) · Immunology
  TNFR:Fc is a fusion protein that binds to tumor necrosis factor (TNF) and prevents it from interacting with its receptors on cell surfaces.
• TNF Inhibitor (W12-W48) · University Hospital, Montpellier · Immunology
  TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce systemic inflammation and immune-mediated tissue damage.
• New Formulation Etanercept · Amgen · Immunology
  New Formulation Etanercept blocks the action of tumor necrosis factor-alpha (TNF-α), reducing inflammation.
• adalimumab (D2E7) · Abbott · Immunology
  Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors.
• administration of Cimzia® · University Hospital, Ghent · Immunology
  Cimzia is a fully human monoclonal antibody that selectively binds to tumor necrosis factor (TNF) and blocks its interaction with cell surface TNF receptors.
• TNF Inhibitor (W0-W12) · University Hospital, Montpellier · Immunology
  TNF inhibitors block tumor necrosis factor (TNF), a key inflammatory cytokine, to reduce inflammation and immune-mediated tissue damage.
• Biologic TNFi · Pfizer · Immunology
  A TNF inhibitor biologic that blocks tumor necrosis factor (TNF) to reduce inflammatory immune responses.

Phase 2 pipeline (1)

• Baminercept alfa 4 · Biogen · Rheumatology
  Baminercept alfa 4 is a fusion protein that targets and binds to the soluble form of tumor necrosis factor (TNF) to prevent its interaction with cell surface TNF receptors.